Company profile
ONKURE THERAPEUTICS, INC.
NASDAQ:OKURBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BOCODEPSIN BESYLATE | phase1_2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03931681 | phase1 | completed | 2019-05-08 | 2021-11-27 | OnKure, Inc. | A Study of OKI-179 in Patients With Solid Tumors |
| NCT06239467 | phase1 | active_not_recruiting | 2024-02-26 | 2026-12-31 | OnKure, Inc. | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer |
| NCT05340621 | phase1_2 | completed | 2022-05-11 | 2025-01-29 | OnKure, Inc. | NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) |
FDA applications (0)
No records yet.